LCLAT1: A Potential Drug Target Or Biomarker (G253558)

Target Name: LCLAT1

NCBI ID: G253558

LCLAT1

LCLAT1: A Potential Drug Target Or Biomarker

LCLAT1 (Lysocardiolipin Acyltransferase 1) is a protein that is expressed in various tissues throughout the body, including the liver, muscle, and heart. It is a key enzyme in the fatty acid oxidation pathway, which is a critical process that helps regulate energy metabolism.

In recent years, researchers have become increasingly interested in LCLAT1 as a potential drug target or biomarker. LCLAT1 has been shown to play a role in the development and progression of various diseases, including obesity, diabetes, and heart disease.

One of the key reasons for the interest in LCLAT1 is its involvement in the production of fatty acids, which are essential for the structure and function of many cellular components. In addition, LCLAT1 has been shown to play a role in the regulation of cellular signaling pathways, including the TGF-β pathway.

Recent studies have also shown that LCLAT1 is involved in the development of various diseases, including obesity, type 2 diabetes, and cardiovascular disease. For example, studies have shown that LCLAT1 is overexpressed in obesity and that inhibiting LCLAT1 has the potential to be a useful treatment for this disease.

In addition to its potential as a drug target, LCLAT1 is also a potential biomarker for a number of diseases. For example, LCLAT1 has been shown to be involved in the regulation of inflammation, which is a key factor in the development of many diseases. In addition, LCLAT1 has been shown to be involved in the regulation of cellular signaling pathways, which can be useful for the diagnosis and treatment of various diseases.

Overall, LCLAT1 is a protein that has the potential to be a drug target or biomarker for a number of diseases. Further research is needed to fully understand its role in the regulation of cellular signaling pathways and its potential as a therapeutic agent.

Protein Name: Lysocardiolipin Acyltransferase 1

Functions: Exhibits acyl-CoA:lysocardiolipin acyltransferase (ALCAT) activity; catalyzes the reacylation of lyso-cardiolipin to cardiolipin (CL), a key step in CL remodeling (By similarity). Recognizes both monolysocardiolipin and dilysocardiolipin as substrates with a preference for linoleoyl-CoA and oleoyl-CoA as acyl donors (By similarity). Also exhibits 1-acyl-sn-glycerol-3-phosphate acyltransferase activity (AGPAT) activity; converts 1-acyl-sn-glycerol-3- phosphate (lysophosphatidic acid or LPA) into 1,2-diacyl-sn-glycerol-3- phosphate (phosphatidic acid or PA) by incorporating an acyl moiety at the sn-2 position of the glycerol backbone (PubMed:16620771). Possesses both lysophosphatidylinositol acyltransferase (LPIAT) and lysophosphatidylglycerol acyltransferase (LPGAT) activities (PubMed:19075029). Required for establishment of the hematopoietic and endothelial lineages (By similarity)

The "LCLAT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LCLAT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets